Drugs / NHWD-870
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06527300 | Apr 2024 → Jun 2025 overdue | — | Zhejiang Wenda Pharma Technology LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NHWD-870 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06527300 ↗ |
| Route | Oral | “Take a fixed dose of NHWD-870 HCl tablets orally.” NCT06527300 ↗ |